Description

Global Radiopharmaceuticals Market Outlook:

Radiopharmaceuticals/Nuclear Medicine Market report gives a comprehensive outlook on radiopharmaceuticals across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on radiopharmaceuticals/nuclear medicine market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application area, route of administration, end user, and geographic regions. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, radiopharmaceuticals/nuclear medicine market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed radiopharmaceuticals market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the Market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in manufacturing, supply and prescribing of radiopharmaceuticals.

Radiopharmaceuticals/Nuclear Medicine Market Size:

Radiopharmaceuticals/Nuclear Medicine Market was valued at US$ 5604 Mn in 2019 and poised to grow at CAGR of 9.2% over 2020-2026. The market for radiopharmaceuticals projected to reach US$ 9326 Mn by 2026 owing to increasing adoption of radiotherapeutic and diagnostic procedures across the globe.

The global radiopharmaceuticals/Nuclear Medicine Market is growing at a significant CAGR due to rising in the prevalence of various types of cancers and cardiovascular diseases. The growing prevalence of various cancers resulted in an increased adoption of radiopharmaceuticals in diagnosis and treatment of several cancers in developed economies. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide.  Moreover, advances in technology such as introduction of PET radiotracers and targeted radioimmunotherapies expected to drive the overall market revenue growth over the forecast period

 

The development of effective radiopharmaceuticals for diagnosis and treatment expected to drive the market revenue growth over the forecast period. The advances in imaging devices with radio-activity are aiding healthcare professionals in effective diagnosis. Moreover, radio-imaging diagnosis is considered as an effective alternative to the conventional diagnosis techniques such as X-rays which expected to boost the market demand for diagnostic radiopharmaceuticals across the globe. In addition, increase in the healthcare expenditure, radiopharmaceuticals abundance, and non-invasiveness in the treatment and diagnostic procedure might bolster the nuclear medicine market over the forecast period.

Geographical Analysis of  Radiopharmaceuticals/Nuclear Medicine Market:

North America market holds the higher revenue share in global radiopharmaceuticals/Nuclear Medicine Market and projected to remain same over the forecast period owing to rising FDA approvals and production of radiopharmaceuticals in the region. Asia Pacific radiopharmaceuticals (nuclear medicine) market projected to grow at significant CAGR over the forecast period in comparison with other regions owing to conducive business environment and rising PET installations in the region

Competition Assessment

Key players profiled in the global Radiopharmaceuticals/Nuclear Medicine Market include:

  • Advanced Accelerator Applications S.A. (France)
  • Bayer AG (Germany)
  • Bracco Imaging S.p.A  (Italy)
  • Cardinal Health, Inc. (U.S.)
  • Eli Lilly and Co. (U.S.)
  • GE Healthcare (U.S.)
  • IBA Molecular Imaging (Belgium)
  • Jubilant Life Sciences Ltd (India)
  • Lantheus Medical Imaging, Inc. (U.S.)
  • Mallinckrodt plc (Ireland)
  • Navidea Biopharmaceutical (U.S.)
  • Nordion, Inc. (Canada)
  • Siemens Healthineers (Germany)

Players in the radiopharmaceuticals/Nuclear Medicine Market are focusing on expanding product portfolio, acquisitions to garner larger market revenue share in global radiopharmaceuticals/Nuclear Medicine Market

Key Findings of the Report:

 

  • Global radiopharmaceuticals/Nuclear Medicine Market expanding at 9.2% CAGR over 2020 to 2026 to reach market value of US$ 8,564 Mn by 2023
  • Based on product type, diagnostic radiopharmaceuticals accounted for larger market revenue share in 2019 owing to wider application in various diagnostic procedures across the regions and expected to grow at significant rate
  • Oncology application segment accounted for larger market revenue share in 2016 expected to remain attractive over the forecast period owing to growing prevalence of various cancers
  • Players are focusing on the production of radiopharmaceuticals to expand market presence in global radiopharmaceuticals market.

Detailed Segmentation

 

By Product Type

  • Diagnostic Radiopharmaceuticals
    • SPECT Radiopharmaceuticals
    • PET Radiopharmaceuticals
  • Therapeutic Radiopharmaceuticals
    • Beta Emitters
    • Alpha emitters
    • Brachytherapy
    • Others

By Application

  • Oncology
  • Neurological disorders
  • Cardiovascular diseases
  • Thyroid
  • Others

By Route of Administration

  • Oral
  • Inhalation
  • Parenteral

By End User

  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Research Institutes 

Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Russia
    • Poland
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Venezuela
    • Rest of Latin America
  • The Middle East and Africa (MEA)
    • Gulf Cooperation Council (GCC) Countries
    • Israel
    • South Africa
    • Rest of MEA

Key Features of the Report:

 

  • The report provides granular level information about the market size, regional market share, historic market (2015-2019) and forecast (2020-2026)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market


Location

GEOGRAPHY

PBI Location Map

  1. Research Methodology
    • Secondary and Primary research
      • Secondary Sources
      • Primary Sources
    • Market Revenue Estimation Methodology
    • Key Assumptions
    • Acronyms
  2. Scope of Study
    • Market Definition
    • Objective of the Research
    • Regions covered in the study
  3. Executive summary
  4. Global Radiopharmaceuticals/Nuclear Medicine Market Dynamics
    • Drivers
      • Economic Drivers
      • Demand Side Drivers
      • Supply Side Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
  5. Unique Features of the Report
    • Competition analysis
    • Regulatory landscape
    • PESTLE analysis
    • Porter’s analysis
  6. Global Radiopharmaceuticals/Nuclear Medicine Market Analysis, By Product Type, 2015 – 2019 and Forecast, 2020 – 2026
    • Diagnostic Radiopharmaceuticals (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals)
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Therapeutic Radiopharmaceuticals (Beta Emitters, Alpha emitters, Brachytherapy, and Others)
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%)
  1. Global Radiopharmaceuticals/Nuclear Medicine Market Forecast, By Application Analysis, 2015 – 2019 and Forecast, 2020 – 2026
    • Oncology
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Neurological disorders
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Cardiovascular diseases
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Thyroid
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Others
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%)
  1. Global Radiopharmaceuticals/Nuclear Medicine Market Forecast, By Route of Administration Analysis, 2015 – 2019 and Forecast, 2020 – 2026
    • Oral
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Inhalation
      • Market Analysis, 2015 – 2019 and Forecast, 2018 – 2026(Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Parenteral
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%)
  1. Global Radiopharmaceuticals/Nuclear Medicine Market Forecast, By End User Analysis, 2015 – 2019 and Forecast, 2020 – 2026
    • Hospitals
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Clinics
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Diagnostic Centers
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Research Institutes
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%)
  1. Radiopharmaceuticals/Nuclear Medicine Market Analysis, By Region, 2015 – 2019 and Forecast, 2020 – 2026
    • North America Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
  2. 1.1. Product Type Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn) and Y-o-Y Growth (%)
    • Diagnostic Radiopharmaceuticals
      • SPECT Radiopharmaceuticals
      • PET Radiopharmaceuticals
    • Therapeutic Radiopharmaceuticals
      • Beta Emitters
      • Alpha emitters
      • Brachytherapy
      • Others
    • Application Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn) and Y-o-Y Growth (%)
      • Oncology
      • Neurological disorders
      • Cardiovascular diseases
      • Thyroid
      • Others
    • Route of Administration Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn) and Y-o-Y Growth (%)
      • Oral
      • Inhalation
      • Parenteral
    • End User Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn) and Y-o-Y Growth (%)
      • Hospitals
      • Clinics
      • Diagnostic Centers
      • Research Institutes
    • Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn) and Y-o-Y Growth (%)
      • US.
      • Canada
    • Europe Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
  3. 2.1. Product Type Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn) and Y-o-Y Growth (%)
    • Diagnostic Radiopharmaceuticals
      • SPECT Radiopharmaceuticals
      • PET Radiopharmaceuticals
    • Therapeutic Radiopharmaceuticals
      • Beta Emitters
      • Alpha emitters
      • Brachytherapy
      • Others
    • Application Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn) and Y-o-Y Growth (%)
      • Oncology
      • Neurological disorders
      • Cardiovascular diseases
      • Thyroid
      • Others
    • Route of Administration Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn) and Y-o-Y Growth (%)
      • Oral
      • Inhalation
      • Parenteral
    • End User Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn) and Y-o-Y Growth (%)
      • Hospitals
      • Clinics
      • Diagnostic Centers
      • Research Institutes
    • Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn) and Y-o-Y Growth (%)
      • UK
      • Germany
      • France
      • Italy
      • Spain
      • Russia
      • Poland
      • Rest of Europe
    • Asia-Pacific Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
  4. 3.1. Product Type Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn) and Y-o-Y Growth (%)
    • Diagnostic Radiopharmaceuticals
      • SPECT Radiopharmaceuticals
      • PET Radiopharmaceuticals
    • Therapeutic Radiopharmaceuticals
      • Beta Emitters
      • Alpha emitters
      • Brachytherapy
      • Others

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

 

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX